Aligos Therapeutics (ALGS): Rasio rega marang prakiraan pendapatan

The prospects of Aligos Therapeutics (ALGS) depend on the integration of NASH and hepatitis B drugs into government procurement. The company's forward P/S confirms market optimism, while 0.40 reflects the latest level of this metric. Partnerships with pharma behemoths for molecule testing are accelerating growth. A narrow specialization in metabolic liver pathologies protects the business from price wars, focusing development on therapeutic efficacy.

Aligos Therapeutics, Inc. - Rasio kapitalisasi marang dodolan sing dikarepake ALGS (periode 04.07.2022 - 13.11.2026)

ALGS (aligos.com): rincian analitis lan laporan miturut indikator

- rega saiki lan proyeksi nilai saham:

Rega saham Aligos Therapeutics, Inc.|ALGS - Prakiraan konsensus analis

- data kapitalisasi bursa:

Nilai pasar Aligos Therapeutics, Inc.|ALGS - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Aligos Therapeutics|ALGS - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku aligos.com|ALGS - Aset Neraca Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas Aligos Therapeutics|ALGS - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Aligos Therapeutics, Inc.|ALGS - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Aligos Therapeutics, Inc.|ALGS - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Aligos Therapeutics|Rasio cepet aligos.com

- rincian asil keuangan lan kelipatan valuasi:

ALGS - Bathi pungkasan|Proyeksi bathi mangsa ngarep Aligos Therapeutics|ALGS - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Aligos Therapeutics, Inc.|ALGS - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Aligos Therapeutics, Inc.|ALGS - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Aligos Therapeutics|ALGS - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan aligos.com|ALGS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Aligos Therapeutics

- indikator volume dodolan lan pendapatan:

ALGS - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan Aligos Therapeutics, Inc.|ALGS - Kapitalisasi marang volume dodolan|Multiplikator Forward P/S Aligos Therapeutics, Inc.

Analisis komprehensif perusahaan:Aligos (ALGS)

The forward P/S ratio reflects the market value of the business relative to projected annual revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward price-to-sales ratio, an investor weighs market expectations against the risks of Aligos Therapeutics (ALGS), whose capitalization depends critically on the success of clinical trials for liver disease treatments.

Pesaing wigati

Multiplikator Forward P/S ARWR (Arrowhead Pharmaceuticals, Inc.)|Multiplikator Forward P/S Mirum Pharmaceuticals, Inc. MIRM|DVAX - Rasio rega marang prakiraan pendapatan|ABUS: Rasio rega marang prakiraan pendapatan|IVA: Multiplikator Forward P/S|GYRE - Rasio kapitalisasi marang dodolan sing dikarepake|ASMB (Assembly Biosciences, Inc.) - Multiplikator Forward P/S|GALT - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Genfit S.A. (GNFT)|DRRX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan BioVie BIVI|Rasio kapitalisasi marang dodolan sing dikarepake Galmed Pharmaceuticals Ltd (GLMD)|NDRA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan HEPA (Hepion Pharmaceuticals)